News und Analysen

Agios Pharmaceuticals (NASDAQ:AGIO), a biotechnology company focused on therapies for rare blood disorders, released its second quarter 2025 earnings on July 31, 2025. The headline was a notable

Huntsman (NYSE:HUN), the global specialty chemicals company serving industries from construction to transportation, reported its financial results for the second quarter on July 31, 2025. The

If you're looking to invest in dividend stocks, one of the most popular ways to do it is with the Schwab U.S. Dividend Equity ETF (NYSEMKT: SCHD). The exchange-traded fund (ETF) has net assets of

Indivior (NASDAQ:INDV), a global pharmaceutical company known for its treatments for opioid use disorder (OUD), reported results on July 31, 2025. The main news was a sharp outperformance compared

Neurocrine Biosciences (NASDAQ:NBIX), a neuroscience-focused biopharma company, delivered a standout earnings report for the second quarter of fiscal 2025, released on July 30, 2025. The report

Shares of AbbVie (NYSE: ABBV) were bouncing along merrily for most of Thursday's trading session, until news of a fresh demand from the White House quashed the rally. Initially, the market was

Throughout 2025, a number of data center stocks have emerged beyond the incumbent players such as Nvidia and Advanced Micro Devices. One company that's witnessed a significant rise in popularity is

Pfizer (NYSE: PFE) has been around for over 175 years, but it became a true household name during the COVID-19 pandemic as one of the main vaccine suppliers. That led to its stock price and revenue

Anika Therapeutics (NASDAQ:ANIK), a medical technology company focused on joint preservation and regenerative therapy products, released its earnings on July 30, 2025. The key news from the release

Five years ago, the eyes of the world were on Pfizer (NYSE: PFE). The big drugmaker was racing to develop a COVID-19 vaccine with its partner, BioNTech (NASDAQ: BNTX). Its stock was poised for a

On Tuesday, Merck (NYSE: MRK) wasn't one of the better-performing pharmaceutical stocks. In contrast to certain peers, the company's share price declined following the release of second-quarter

AstraZeneca (NASDAQ: AZN) reported an estimates-busting quarter Tuesday morning, and a satisfied market rewarded the company for it. At market close the sturdy pharmaceutical stock had risen by

In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD). To learn more, check out the short video, consider subscribing, and click the special offer link below.

Alkermes Plc (NASDAQ:ALKS), a neuroscience-focused biopharmaceutical company, released its second quarter 2025 results on July 29, 2025. The standout news was a significant outperformance versus

Merck (NYSE:MRK), a leading developer of prescription medicines, vaccines, and animal health products, released its second-quarter 2025 results on July 29, 2025. The most notable news was a beat on

Healthcare stocks aren't exactly known for offering large yields, with the average healthcare stock at just 1.8% or so. You can do better than that and get reliable dividend stocks while you are at

Exelixis (NASDAQ:EXEL), an oncology-focused biotech, reported results for Q2 2025 on July 28, 2025. For the period, the company delivered non-GAAP earnings per share (EPS) of $0.75 in Q2 FY2025

Over the long run, dividends can make a significant difference in your returns, whether you choose to reinvest the payouts or retain the cash for other purposes. However, many companies that offer

Vertex Pharmaceuticals (NASDAQ: VRTX) has been a terrific stock to own over the past decade. The stock has outperformed the market over this period, thanks to consistent financial results and

You'd think that companies with long, successful track records and market caps in the hundreds of billions of dollars would be viewed as relatively formidable. However, that's not always the case.

Investors looking to grow their passive income stream with dividend stocks have two basic options. Dividend payers that raise their payouts rapidly tend to offer low yields up front, while

AT&T (NYSE: T) has quietly been a great-performing stock over the past couple of years, but it has pulled back after the company failed to raise its guidance when it reported its second quarter